Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

NCT04884399 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG: CMAB818
DRUG: Lucentis®

Sponsor

Shanghai Biomabs Pharmaceutical Co., Ltd.